Pliant Therapeutics, Inc. (PLRX)
NASDAQ: PLRX · Real-Time Price · USD
13.21
-0.09 (-0.68%)
Dec 20, 2024, 4:00 PM EST - Market closed
Pliant Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Pliant Therapeutics stock have an average target of 40.5, with a low estimate of 33 and a high estimate of 45. The average target predicts an increase of 206.59% from the current stock price of 13.21.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 8, 2024.
Analyst Ratings
The average analyst rating for PLRX stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
Buy | 4 | 3 | 4 | 4 | 4 | 4 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 7 | 6 | 7 | 7 | 7 | 7 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $38 | Strong Buy | Reiterates | $38 | +187.66% | Nov 8, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $38 | Strong Buy | Reiterates | $38 | +187.66% | Sep 13, 2024 |
Leerink Partners | Leerink Partners | Buy Initiates $33 | Buy | Initiates | $33 | +149.81% | Sep 9, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $36 → $38 | Strong Buy | Maintains | $36 → $38 | +187.66% | Aug 12, 2024 |
Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Aug 8, 2024 |
Financial Forecast
Revenue This Year
n/a
from 1.58M
Revenue Next Year
1.94M
EPS This Year
-3.71
from -2.75
EPS Next Year
-4.10
from -3.71
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | n/a | 15.8M | 21.0M | |||
Avg | n/a | 1.9M | 5.1M | |||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | - | - | 983.6% | |||
Avg | - | - | 163.2% | |||
Low | - | - | - |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | -3.75 | -3.27 | -3.76 | |||
Avg | -3.71 | -4.10 | -4.32 | |||
Low | -3.64 | -5.13 | -6.51 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | - | - | - | |||
Avg | - | - | - | |||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.